Could ARGOS THERAPEUTICS INC (OTCMKTS:ARGS) See a Reversal After Less Sellers Came In?

May 16, 2018 - By Vivian Currie

Argos Therapeutics, Inc. (OTCMKTS:ARGS) Logo

Investors sentiment increased to 0.85 in Q4 2017. Its up 0.22, from 0.63 in 2017Q3. It increased, as 8 investors sold Argos Therapeutics, Inc. shares while 5 reduced holdings. 6 funds opened positions while 5 raised stakes. 2.48 million shares or 6.25% less from 2.64 million shares in 2017Q3 were reported.
Royal Financial Bank Of Canada reported 1,351 shares. 7,526 are held by Blackrock. Bancorp Of New York Mellon Corp has invested 0% in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Virtu Fincl Limited Liability Company reported 0% of its portfolio in Argos Therapeutics, Inc. (OTCMKTS:ARGS). 20,074 were reported by Credit Suisse Ag. Meeder Asset Management invested 0% of its portfolio in Argos Therapeutics, Inc. (OTCMKTS:ARGS). State Street Corp has invested 0% in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Vanguard Gp owns 1.05 million shares. Morgan Stanley stated it has 0% in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Keybank Natl Association Oh accumulated 119,515 shares. Stifel Fin has 0% invested in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Northern Trust reported 43,244 shares stake. Moreover, Guggenheim Capital Lc has 0% invested in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Wasatch accumulated 0% or 643,265 shares. California Employees Retirement owns 94,800 shares for 0% of their portfolio.

The stock of ARGOS THERAPEUTICS INC (OTCMKTS:ARGS) registered a decrease of 91.01% in short interest. ARGS’s total short interest was 65,500 shares in May as published by FINRA. Its down 91.01% from 728,400 shares, reported previously.

The stock decreased 9.43% or $0.018 during the last trading session, reaching $0.172. About 67,166 shares traded. Argos Therapeutics, Inc. (OTCMKTS:ARGS) has declined 87.69% since May 16, 2017 and is downtrending. It has underperformed by 99.24% the S&P500.

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company has market cap of $1.82 million. The firm develops immunotherapies based on its proprietary technology platform, Arcelis. It currently has negative earnings. The Company’s product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: